Expansion of Integrated AI Solution for Diabetic Retinopathy Screening in Thailand: An Implementation Research

Rajavithi Hospital0 sites34,500 target enrollmentOctober 3, 2022

ConditionsDiabetic Retinopathy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Diabetic Retinopathy
Sponsor: Rajavithi Hospital
Enrollment: 34500
Primary Endpoint: Effectiveness of AI in diabetic retinopathy screening
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Efficiency and effectiveness of real-world diabetic retinopathy screening by artificial intelligent (AI) are limited. Investigators will implement AI for diabetic retinopathy screening in 13 health districts in Thailand and investigate the efficiency, effectiveness as well as patients and health care personnel's satisfaction by an implementation research.

Registry

clinicaltrials.gov

Start Date

October 3, 2022

End Date

September 30, 2023

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Rajavithi Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Type 1 or 2 diabetes mellitus patients whose name are in primary hospital record
•No full-time ophthalmologists in those primary hospital
•Age more than or equal to 18 years
•Eligible for fundus photo imaging at least 1 eye

Exclusion Criteria

•Type 1 or 2 diabetes mellitus patients whose name are in primary hospital record that have full-time ophthalmologists
•Patients who previously diagnosed with other causes of macular edema, for example, Age-related Macular Degeneration, Radiation Retinopathy, Retinal Vein Occlusion etc.
•History of retinal laser or surgery
•Other ocular diseases that require referral to ophthalmologists
•Not eligible for fundus photo imaging for both eyes (any causes)